| Abstrakt: |
A recent study conducted in Japan found that caplacizumab, a treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP), was effective in reducing the recurrence of iTTP. The study aimed to assess changes in ADAMTS13 activity/inhibitor levels during caplacizumab treatment. The results showed that early administration of rituximab in addition to caplacizumab may prevent iTTP recurrence with inhibitor boosting. This research suggests that caplacizumab, along with therapeutic plasma exchange and immunosuppression, may reduce the risk of ADAMTS13 inhibitor boosting in patients with iTTP. [Extracted from the article] |
